share_log
  • Headlines
  • Relmada Therapeutics Announced That The Pre-planned Interim Analysis Of Reliance II Phase 3 Study Indicated That The Study Is Futile And Is Unlikely To Meet The Primary Efficacy Endpoint With Statistical Significance

Relmada Therapeutics Announced That The Pre-planned Interim Analysis Of Reliance II Phase 3 Study Indicated That The Study Is Futile And Is Unlikely To Meet The Primary Efficacy Endpoint With Statistical Significance

Benzinga ·  Dec 4 07:33
  • Reliance II is designed to evaluate REL-1017 as an adjunctive treatment for major depressive disorder (MDD), to be used in combination with other approved anti-depressants. No new safety signals were reported.
  • The Data Monitoring Committee did not identify any new safety concerns
  • Relmada to evaluate potential next steps for the REL-1017 program
  • Relmada to continue to focus on the development of REL-P11 for metabolic disease
  • Relmada is well capitalized with approximately $54.1 million in cash and cash equivalents as of September 30, 2024
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated